Last updated on October 2018

Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases


Brief description of study

The purpose of this study is to compare overall survival rates of colorectal cancer patients with multi-organ metastases with an indication for first line systemic treatment randomized for treatment with combination chemotherapy or treatment with combination chemotherapy and additional maximal tumor debulking including surgical tumor resection, RFA, (DEBIRI-)TACE and SBRT, depending on best clinical judgement according to a standardized treatment algorithm. Our hypothesis is that maximal tumor debulking in addition to systemic treatment with chemotherapy and biologicals will provide an improvement in progression free and overall survival in this patient group.

Clinical Study Identifier: NCT01792934

Find a site near you

Start Over

Meander Medisch Centrum

Amersfoort, Netherlands
  Connect »

Amstelveen Ziekenhuis

Amstelveen, Netherlands
  Connect »

VU Medical Center

Amsterdam, Netherlands
  Connect »

Deventer Ziekenhuis

Deventer, Netherlands
  Connect »

Maxima Medisch Centrum

Eindhoven, Netherlands
  Connect »

Spaarne ziekenhuis

Hoofddorp, Netherlands
  Connect »

Sint Antonius Ziekenhuis

Nieuwegein, Netherlands
  Connect »

UMC Sint Radboud

Nijmegen, Netherlands
  Connect »

Bravis ziekenhuis

Roosendaal, Netherlands
  Connect »

Franciscus Gasthuis

Rotterdam, Netherlands
  Connect »

IJsselland ziekenhuis

Rotterdam, Netherlands
  Connect »

Maasstadziekenhuis

Rotterdam, Netherlands
  Connect »

Jeroen Bosch Ziekenhuis

Zaltbommel, Netherlands
  Connect »

Isala Klinieken

Zwolle, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.